Development and validation of combined symptom‐medication scores for allergic rhinitis* Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Background

    Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs.

    Methods

    We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air® , and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]).

    Results

    We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820).

    Conclusion

    The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.

authors

  • Sousa‐Pinto, Bernardo
  • Azevedo, Luís Filipe
  • Jutel, Marek
  • Agache, Ioana
  • Canonica, G Walter
  • Czarlewski, Wienczyslawa
  • Papadopoulos, Nikolaos G
  • Bergmann, Karl‐Christian
  • Devillier, Philippe
  • Laune, Daniel
  • Klimek, Ludger
  • Anto, Aram
  • Anto, Josep M
  • Eklund, Patrik
  • Almeida, Rute
  • Bedbrook, Anna
  • Bosnic‐Anticevich, Sinthia
  • Brough, Helen A
  • Brussino, Luisa
  • Cardona, Victoria
  • Casale, Thomas
  • Cecchi, Lorenzo
  • Charpin, Denis
  • Chivato, Tomás
  • Costa, Elisio M
  • Cruz, Alvaro A
  • Dramburg, Stephanie
  • Durham, Stephen R
  • De Feo, Giulia
  • Gerth van Wijk, Roy
  • Fokkens, Wystke J
  • Gemicioglu, Bilun
  • Haahtela, Tari
  • Illario, Maddalena
  • Ivancevich, Juan Carlos
  • Kvedariene, Violeta
  • Kuna, Piotr
  • Larenas‐Linnemann, Désirée E
  • Makris, Michael
  • Mathieu‐Dupas, Eve
  • Melén, Erik
  • Morais‐Almeida, Mario
  • Mösges, Ralph
  • Mullol, Joaquim
  • Nadeau, Kari C
  • Pham‐Thi, Nhân
  • O’Hehir, Robyn
  • Regateiro, Frederico S
  • Reitsma, Sietze
  • Samolinski, Boleslaw
  • Sheikh, Aziz
  • Stellato, Cristiana
  • Todo‐Bom, Ana
  • Tomazic, Peter Valentin
  • Toppila‐Salmi, Sanna
  • Valero, Antonio
  • Valiulis, Arunas
  • Ventura, Maria Teresa
  • Wallace, Dana
  • Waserman, Susan
  • Yorgancioglu, Arzu
  • De Vries, Govert
  • van Eerd, Michiel
  • Zieglmayer, Petra
  • Zuberbier, Torsten
  • Pfaar, Oliver
  • Almeida Fonseca, João
  • Bousquet, Jean

publication date

  • July 2022